Welcome to GMP Part 1 — PIC/S GMP Guide
This course provides a comprehensive introduction to Good Manufacturing Practice regulations as described in PIC/S GMP Part 1, which governs the manufacture of medicinal products for human use. It is suitable for anyone new to, or refreshing their knowledge of, GMP-regulated pharmaceutical environments.
What This Course Covers
PIC/S GMP Part 1 sets out the fundamental requirements for the manufacture of medicinal products — from quality management systems and personnel responsibilities through to production controls, documentation, and self-inspection. This course translates those requirements into practical, understandable knowledge for anyone working in or adjacent to pharmaceutical manufacturing.
Who Should Complete This Course?
- New or existing Manufacturing and Quality department personnel
- Suppliers and contractors involved in operations related to medicinal products
- Anyone requiring a GMP training certificate for employment or compliance purposes
- Individuals applying for roles in the pharmaceutical industry
- Personnel returning to the industry after a career break
Course Structure
The course is divided into nine content modules covering all major areas of PIC/S GMP Part 1. Each module ends with a 3-question knowledge check (70% required). After completing all modules, a 15-question Final Assessment must be passed at 80% or higher to earn your Certificate of Completion.
⏱ Estimated Duration
Allow 1.5 to 2.5 hours to complete the course including the Final Assessment. You may pause and return at any time — the course is available 24/7 for 12 months from date of enrolment.
🎓 Certificate
Your Certificate of Completion meets general PIC/S GMP and EU GMP regulatory expectations. It can be forwarded to your Quality Manager, Supervisor, or HR department and attached to job applications.
📋 Prerequisites
No formal prerequisites. The 10 Golden Rules of GMP course is recommended as helpful orientation, particularly for those with no prior GMP experience.
⚠ Scope
This course should be combined with onsite training and workplace supervision. eLearning does not replace product-specific or site-specific GMP training programs.
Recommended Follow-On Courses
After completing GMP Part 1, the following courses are recommended to deepen your understanding:
- Good Record-Keeping Practice (Good Documentation Practice)
- GMP Part 2 (Active Pharmaceutical Ingredients)
- PIC/S Annexes 1–20 (specialist manufacturing topics)
- Good Laboratory Practice (GLP) for nonclinical studies
- GMP Refresher Training for experienced professionals
- FDA CFR 210 & 211 / CFR 800 & 820 for US-specific requirements
Regulatory Framework & PIC/S Overview
Good Manufacturing Practice regulations exist to protect patients. This module introduces the global regulatory framework for pharmaceutical GMP — with a focus on PIC/S, the international harmonisation body whose guidelines underpin GMP requirements across more than 55 regulatory authorities worldwide.
What is PIC/S?
The Pharmaceutical Inspection Co-operation Scheme (PIC/S) is an international cooperative arrangement between regulatory authorities that promotes the harmonisation of GMP standards globally. Established in 1970, PIC/S now comprises over 55 member authorities across Europe, the Americas, Asia-Pacific, Africa, and the Middle East.
PIC/S develops and maintains the internationally recognised PIC/S GMP Guide — a set of harmonised GMP guidelines that form the basis of pharmaceutical GMP requirements in most member countries. Compliance with the PIC/S GMP Guide is, for most purposes, equivalent to compliance with EU GMP requirements.
The PIC/S GMP Guide applies to all aspects of the manufacture of medicinal products including bulk chemical and biological processes, sterile manufacturing, herbal products, and investigational medicinal products. It is updated regularly to reflect advances in pharmaceutical science and regulatory expectations.
Structure of the PIC/S GMP Guide
📗 Part I — Basic Requirements
Core GMP requirements for finished medicinal products including quality management, personnel, premises, documentation, production, quality control, and self-inspection.
📘 Part II — Active Substances
Based on ICH Q7, Part II covers GMP requirements for Active Pharmaceutical Ingredients (APIs). Covered in GMP Part 2 training.
📙 Annexes 1–20
Supplementary requirements for specific manufacturing types including sterile products (Annex 1), biologicals (Annex 2), radiopharmaceuticals (Annex 3), and more.
📕 ICH Guidelines
International Council for Harmonisation (ICH) guidelines (Q8 Quality by Design, Q9 Risk Management, Q10 Pharmaceutical Quality System) integrate with PIC/S GMP.
Why Does GMP Compliance Matter?
GMP regulations exist because pharmaceutical products can cause serious harm if they are contaminated, sub-potent, super-potent, or mislabelled. Unlike many other consumer goods, patients cannot independently verify the quality of a medicine — they must rely on the manufacturer and the regulator to ensure it is safe and effective.
GMP failures can result in patient harm or death, product recalls and market withdrawals, warning letters from regulatory authorities, facility shutdowns, import alerts, financial penalties, and criminal prosecution of responsible individuals. Compliance is not optional — it is the minimum standard expected of every person in a GMP-regulated role.
Contract Manufacturing and GMP
When a medicinal product is manufactured under contract, both the contract giver and contract acceptor share GMP responsibilities. The contract giver remains ultimately responsible for the quality of the product. All contract manufacturing arrangements must be covered by a written contract that clearly defines GMP responsibilities.
PIC/S member authorities have mutual recognition arrangements that mean a GMP inspection conducted by one member authority is generally accepted by others. This reduces duplication of inspections for internationally operating manufacturers and facilitates global supply chains.
GMP Terms & Definitions
Precision in language is fundamental to GMP compliance. Regulatory documents, SOPs, and batch records use specific defined terms that carry exact meanings. Misunderstanding key terms can lead to misinterpretation of requirements and compliance failures.
Why Definitions Matter in GMP
GMP regulations are legal documents. Words like "shall," "should," and "may" carry distinct and different obligations. Understanding the precise meaning of regulatory terminology ensures that requirements are correctly interpreted and implemented.
"Shall" = mandatory requirement (must be done). "Should" = recommended but not absolutely required (strong expectation). "May" = permitted, at the manufacturer's discretion. Always distinguish between these when reading GMP guidance.
Key GMP Terms and Their Definitions
Date formats in GMP records must be unambiguous. The date format DD-MON-YYYY (e.g., 15-JAN-2025) or DD/MMM/YYYY is preferred in international GMP records because numeric-only formats (01/02/03) can be misread differently across countries. Always use the format specified in your site's SOPs — and apply it consistently.
Pharmaceutical Quality System (PQS)
The Pharmaceutical Quality System (PQS) is the overarching framework within which all GMP activities are managed. Aligned with ICH Q10, the PQS ensures that medicinal products are designed, manufactured, controlled, stored, and distributed to a standard appropriate for their intended use.
What is a Pharmaceutical Quality System?
The PQS is a comprehensive management system that integrates GMP and the ICH quality guidelines (Q8, Q9, Q10) to create a holistic approach to pharmaceutical quality. It builds on ISO quality management principles and applies them specifically to the pharmaceutical context — with the patient as the ultimate focus.
The PQS should enable the achievement of product realisation, establish and maintain a state of control, and facilitate continual improvement. Senior management has ultimate responsibility for the PQS and must demonstrate active leadership and commitment to quality across the organisation.
Key Elements of the PQS
📋 Quality Policy
A formal statement from senior management committing the organisation to quality. Sets the tone for quality culture and defines the organisation's quality objectives.
🔄 Quality Manual / Site Master File
Describes the organisation's quality management system. The Site Master File (SMF) provides a summary of GMP activities to regulatory authorities — required in EU and many PIC/S jurisdictions.
📊 Management Review
Senior management must periodically review the PQS to assess its effectiveness. Inputs include CAPA status, audit findings, complaints, OOS results, and deviation trends.
⚙️ CAPA System
Corrective and Preventive Action — the mechanism for identifying, investigating, and resolving quality problems. A well-functioning CAPA system is a hallmark of a mature PQS.
🔀 Change Control
A formal system for managing changes to processes, equipment, materials, facilities, and systems. All GMP changes must be assessed for impact and documented before implementation.
🔍 Self-Inspection
Regular internal audits to verify that the PQS is functioning effectively. Findings must be documented and actioned through CAPA. PIC/S GMP Chapter 9 specifically requires a self-inspection programme.
Quality Culture and Senior Management Commitment
A PQS is only as effective as the culture within which it operates. Senior management must visibly and actively demonstrate commitment to quality — not merely sign off on policy documents. This includes providing adequate resources, participating in quality reviews, and setting expectations that quality is never compromised for commercial reasons.
Modern PQS design incorporates Quality by Design (QbD) principles from ICH Q8. By defining the target product profile and understanding the design space, manufacturers can build robustness into their products from the outset — reducing the risk of quality failures during commercial manufacturing.
Product Quality Reviews (PQRs)
GMP requires manufacturers to conduct periodic Quality Reviews of each marketed product — typically annually. PQRs review batch data, test results, deviations, OOS events, complaints, recall information, and change history to evaluate product consistency and identify improvement opportunities. PQRs are a key tool for demonstrating a state of control.
The PQR (or Annual Product Review) is a retrospective summary — it does not replace the need for ongoing real-time process monitoring. Both are required. Trends identified through ongoing monitoring should be investigated before they become confirmed quality failures.
Personnel, Suppliers & Contractors
GMP places clear obligations on personnel at all levels — from the CEO to the production operator — as well as on external parties including contract manufacturers, laboratories, and suppliers. Responsibilities must be defined, understood, and fulfilled at every level of the organisation.
Organisational Requirements
Manufacturers must have a sufficient number of personnel with the appropriate qualifications, knowledge, skills, and experience to carry out all the tasks for which they are responsible. The organisational structure must be documented, and key responsibilities must be assigned to named individuals.
There shall be a sufficient number of personnel with the necessary qualifications and practical experience. Senior management shall establish and maintain an adequate organisational structure, personnel, and equipment to achieve the PQS objectives. Key personnel responsibilities shall be defined in written job descriptions.
Key GMP Personnel Roles
🔒 Qualified Person (QP)
Legally required in EU/PIC/S jurisdictions. Certifies each batch before release. Named in the manufacturer's licence. Must meet defined educational and experience requirements.
🏭 Head of Production
Responsible for production operations in compliance with approved procedures. Ensures equipment, facilities, and materials are GMP-compliant. Jointly responsible for batch record review and approval with QC/QA.
🔬 Head of Quality Control
Responsible for approving or rejecting raw materials, intermediates, and finished products. Ensures all required testing is performed and results are evaluated against specification.
🛡 Head of Quality Assurance
Responsible for the overall Quality Management System — document control, CAPA, deviations, audits, training, change control, and compliance oversight. Independent of production.
Supplier Qualification and Oversight
Manufacturers are responsible for ensuring that all materials — starting materials, reagents, solvents, packaging materials — are sourced from approved, qualified suppliers. The supplier qualification process involves assessment of the supplier's GMP compliance before use, and ongoing oversight to ensure continued compliance.
Supplier Qualification Steps
- Assess supplier against defined qualification criteria
- Request and review supplier's GMP documentation (audit reports, certificates)
- Conduct on-site audit where appropriate (especially for API suppliers)
- Establish written quality agreements covering GMP responsibilities
- Approve supplier for inclusion on the Approved Supplier List (ASL)
- Re-qualify suppliers periodically and following any significant changes
Contract Laboratory Requirements
When quality control testing is outsourced to a contract laboratory, all requirements applicable to in-house laboratories apply equally. The contract laboratory must be assessed and approved. A written contract must define responsibilities. The contract giver may not delegate responsibility for the quality of the results.
Contractors working in GMP areas must comply with all applicable GMP requirements — including training, hygiene, gowning, and documentation. A contractor who introduces contamination or violates GMP procedures is subject to the same consequences as a direct employee. Contractor GMP compliance must be managed through formal agreements and oversight.
Self-Inspections and Audit Readiness
All GMP personnel should be prepared for self-inspections and regulatory authority audits at any time. Self-inspections are required by PIC/S GMP Chapter 9. They must be planned, systematic, and conducted by competent, independent personnel. Findings must be documented and closed through CAPA with defined timelines.
Production Quality Controls
Production quality controls are the checks, tests, and monitoring activities that ensure medicinal products are manufactured to their intended specifications at every stage — from raw material receipt through to finished product release. They are the practical implementation of quality within the manufacturing process.
Production Planning and Scheduling
All production activities must be planned and performed in accordance with written procedures and batch manufacturing records. Planning must ensure that adequate time, personnel, materials, and equipment are available, and that cross-contamination risks are identified and controlled.
Batch Manufacturing Records (BMRs)
A Batch Manufacturing Record is created for each batch of product and captures the complete manufacturing history. It must include or reference:
- The name, batch number, and strength of the product
- Date(s) of manufacture
- Identity and quantity of each starting material dispensed
- All in-process control results and actions taken
- Equipment identification numbers
- Environmental monitoring results where relevant
- All deviations and their disposition
- Signatures of operators and reviewers at each critical step
In-Process Controls (IPCs)
In-Process Controls are measurements, checks, or tests performed during manufacturing to monitor the process and ensure the product is developing within acceptable parameters. They allow corrective action to be taken before the batch is completed — not after.
In-process controls and monitoring shall be performed using validated methods. The results shall be recorded and form part of the batch record. Any excursion from established parameters shall be investigated and documented. Batch processing shall not continue if critical in-process tests have failed.
💊 Tablet Manufacturing IPCs
Weight variation, hardness, friability, disintegration time, thickness — checked at defined intervals throughout compression. Results determine whether production continues or must stop.
💉 Sterile Manufacturing IPCs
Fill volume, container closure integrity, filter integrity testing, bioburden, endotoxin/pyrogen testing — critical controls for patient safety in parenteral products.
🌡 Environmental Monitoring
Routine monitoring of air, surfaces, and personnel in controlled manufacturing areas for particulate and microbial contamination. Alert and action limits trigger investigations.
🏷 Line Reconciliation
At the end of each batch, all materials, labels, and product units are reconciled. Unexplained discrepancies must be investigated before the batch is released.
Starting Material Controls
All starting materials (APIs, excipients, packaging) must be released by QC before use. Materials in quarantine must not be used. Every container of incoming material must be sampled and tested (or released against a Certificate of Analysis with appropriate verification) before use in production.
Finished Product Release
Finished products must not be released until the Qualified Person (or designated QA authority) has confirmed that the batch has been manufactured and tested in compliance with all requirements. Release is a formal act — not a default outcome of passing tests.
A batch that has failing in-process controls or OOS final product results must not be released on the basis that "results have always been fine before." Every batch must stand on its own complete, compliant data. Decisions to release non-conforming product require formal quality risk management and regulatory notification where applicable.
Good Documentation Practice
Good Documentation Practice (GDP) — not to be confused with Good Distribution Practice — is the set of standards governing how GMP records and documents are created, corrected, retained, and managed. Inadequate documentation is one of the most commonly cited findings in regulatory inspections worldwide.
The Fundamental Rule of GMP Documentation
In GMP, if an activity is not documented, it is assumed not to have occurred. Records are the only way to demonstrate compliance to a regulatory inspector who was not present when the work was done. This principle applies to every GMP activity — from equipment cleaning to analyst training to QA batch review.
Good documentation constitutes an essential part of the quality assurance system. Written procedures, instructions and records ensure traceability, and documents must be designed, prepared, reviewed, and distributed with care. They must be approved, signed, and dated by appropriate and authorised persons.
ALCOA+ Data Integrity Framework
All GMP data — whether on paper or electronic — must comply with the ALCOA+ framework to be considered compliant. Regulatory authorities globally have significantly increased enforcement actions related to data integrity failures in recent years.
A — Attributable
Every entry must identify who recorded it and when. Initials alone are insufficient unless a key linking initials to the full name is available.
L — Legible
Records must be permanently readable. Pencil, erasable pen, and correction fluid are prohibited. Entries must not be obscured or overwritten.
C — Contemporaneous
Data must be recorded at the time the activity occurs — not from memory later. Pre-dated or backdated records are a serious violation.
O — Original
The first recording is the original. Transcriptions must be traceable to the original. Data must not be copied to a clean sheet to conceal errors.
A — Accurate
Records must reflect exactly what was observed or measured. Rounding, estimating, or adjusting values is not acceptable without documented justification.
+ (Complete, Consistent, Enduring, Available)
No blank fields. Consistent with related records. Stored durably for the retention period. Accessible when needed by authorised personnel.
Correcting Errors in GMP Records
Errors in paper GMP records must be corrected using a specific, compliant method. The use of any technique that obscures the original entry constitutes a data integrity violation, regardless of intent.
Step 1: Draw a single horizontal line through the incorrect entry so that the original remains clearly readable.
Step 2: Write the correct entry nearby.
Step 3: Initial (or sign) the correction and add the date.
Step 4: If the correction might appear suspicious, add a brief reason (e.g., "Transcription error").
NEVER use: Correction fluid, erasers, multiple lines, overwriting, or anything that obscures the original entry.
Document Types in GMP
- Standard Operating Procedures (SOPs): Step-by-step instructions for performing defined tasks
- Batch Manufacturing Records (BMRs): Production history for each manufactured batch
- Specifications: Acceptance criteria for materials and finished products
- Test Methods: Validated procedures for analytical testing
- Deviation Reports: Documentation of departures from approved procedures
- Change Control Records: Documentation of approved changes to validated systems
- Calibration Records: Evidence that measuring instruments meet accuracy requirements
- Training Records: Evidence that personnel are trained for their assigned duties
Electronic Records and 21 CFR Part 11 / EU GMP Annex 11
Electronic records in GMP systems must have validated audit trails that capture who made changes, what was changed, and when. Access controls must prevent unauthorised entry or modification. Backup and disaster recovery procedures must ensure records are not lost. Hybrid systems (electronic data with paper printouts) require careful management to ensure the original electronic data is the primary record.
Risk Management — ICH Q9
Quality Risk Management (QRM) is a systematic process for the assessment, control, communication, and review of risks to the quality of medicinal products. Formalised in ICH Q9, it provides a science- and evidence-based framework for making better decisions about quality, safety, and efficacy risks — all focused on protecting the patient.
What is Quality Risk Management?
Quality Risk Management applies structured risk thinking to pharmaceutical manufacturing decisions. Rather than treating all risks equally, QRM helps manufacturers identify what matters most, focus resources where the risk is greatest, and make defensible, documented decisions about how to control identified risks.
The evaluation of the risk to quality shall be based on scientific knowledge and ultimately link to the protection of the patient. The level of effort, formality, and documentation of the quality risk management process should be commensurate with the level of risk. Two primary principles: (1) the evaluation of risk should be evidence-based; (2) the level of effort applied should be proportionate to the level of risk.
The ICH Q9 Risk Management Process
1️⃣ Risk Assessment
Identify hazards. Analyse the likelihood and severity of potential harm. Evaluate detectability. The output is a risk estimate — typically expressed as a Risk Priority Number (RPN) or risk level.
2️⃣ Risk Control
Reduce the risk to an acceptable level. Risk reduction can eliminate the cause, reduce the probability of occurrence, or reduce the severity of harm. Accept any residual risk. Document the rationale.
3️⃣ Risk Communication
Share risk information between decision makers and stakeholders. Risk assessments must be communicated to those who need to act on them — not just filed in a folder.
4️⃣ Risk Review
Periodically review risk assessments to ensure they remain current. New information (e.g., adverse events, OOS results, audit findings) may change the risk profile and require re-assessment.
Common QRM Tools
- FMEA (Failure Mode and Effects Analysis): Systematic identification of potential failure modes, their effects, and preventive controls
- Fault Tree Analysis (FTA): Top-down identification of causes that could lead to a defined failure event
- HACCP (Hazard Analysis and Critical Control Points): Identification of critical control points to prevent safety hazards — adapted from food industry use
- Cause-and-Effect (Ishikawa) Diagrams: Visual mapping of potential causes of a quality problem across categories (People, Process, Equipment, Materials, Environment)
- Risk Ranking and Filtering: Comparison and prioritisation of multiple risks to focus resources appropriately
Risk Assessment in Practice
Risk is typically assessed across three dimensions:
ICH Q9 requires that the effort and formality of risk management be proportionate to the level of risk. A low-risk activity (e.g., changing a supplier of disposable gloves) warrants a simple, brief risk assessment. A high-risk change (e.g., modifying a sterile fill process) warrants comprehensive FMEA, validation, and regulatory notification. Applying equal formality to all decisions is itself a risk management failure.
Regulatory Authorities & Inspections
Pharmaceutical manufacturers operate under the oversight of national and international regulatory authorities whose primary mandate is protecting public health. Understanding who the key regulators are, what they expect, and how inspections work is essential for every GMP professional.
Key Global Regulatory Authorities
🇺🇸 FDA — United States
Food and Drug Administration. Regulates drugs (21 CFR Parts 210/211), biologics, and medical devices (21 CFR Part 820). Conducts inspections globally and can issue Warning Letters, Import Alerts, and Consent Decrees.
🇦🇺 TGA — Australia
Therapeutic Goods Administration. PIC/S member. Regulates therapeutic goods including medicines, medical devices, and blood products. Issues manufacturing licences and conducts GMP compliance audits.
🇪🇺 EMA — European Union
European Medicines Agency. Coordinates the scientific evaluation of medicines in the EU. GMP inspections are carried out by national competent authorities (e.g., ANSM in France, BfArM in Germany) under EudraLex Vol. 4.
🇬🇧 MHRA — United Kingdom
Medicines and Healthcare products Regulatory Agency. Post-Brexit, operates independently of EMA. Inspects manufacturing sites for UK GMP compliance. Issues GMP Certificates of Compliance to PIC/S GMP standards.
🇯🇵 PMDA — Japan
Pharmaceuticals and Medical Devices Agency. PIC/S member. Regulates pharmaceutical manufacturing in Japan. Applies Japanese GMP standards harmonised with PIC/S/ICH guidelines.
🇨🇦 Health Canada
PIC/S member. Regulates therapeutic products including drugs and medical devices in Canada. Conducts GMP inspections and issues Drug Establishment Licences (DEL) to compliant manufacturers.
The GMP Inspection Process
Regulatory GMP inspections may be announced (with advance notice) or unannounced. In either case, the facility must be prepared to demonstrate compliance at all times. Understanding the inspection process reduces anxiety and improves outcomes.
Typical Inspection Structure
- Opening meeting: Inspectors introduce themselves and outline the scope of the inspection
- Facility tour: Walk-through of manufacturing areas, laboratories, warehouses
- Document review: Examination of batch records, SOPs, training records, deviation logs, CAPA records
- System reviews: Deep-dive into specific quality systems (validation, change control, complaints)
- Personnel interviews: Direct questioning of personnel at all levels to test knowledge and verify practice
- Closing meeting: Inspectors present preliminary findings (observations/deficiencies)
Inspection Finding Classifications
🔴 Critical Deficiency
A deficiency that has produced, or could produce, a significant risk to patient health or is a serious violation of GMP. May result in immediate regulatory action including suspension of manufacturing or product recall.
🟡 Major Deficiency
A non-critical deficiency that indicates a failure of the quality system that could result in product non-compliance or represents a significant deviation from GMP requirements. Multiple majors may constitute a critical finding.
🟢 Other / Minor Deficiency
A deficiency that cannot be classified as critical or major but indicates a departure from GMP requirements. Accumulation of minor findings may indicate a systemic problem.
📋 Observation
A comment or finding that does not constitute a deficiency but highlights an area for improvement. Observations should be taken seriously — they may become deficiencies at the next inspection if not addressed.
An FDA Warning Letter is a public, formal notification of serious GMP violations. Warning letters are published on the FDA website and name specific individuals. An Import Alert may be issued concurrently, stopping all product from the cited facility from entering the US market. Responding to a Warning Letter requires significant resources, remediation programmes, and may take years to resolve.
Respond to all inspection findings with genuine CAPA — not cosmetic fixes. Regulatory authorities conduct follow-up inspections and will verify that corrective actions have been effectively implemented. Failure to implement CAPA adequately can escalate the regulatory response significantly.
10 Golden Rules & GMP Compliance Culture
Regulations and systems can only achieve so much. The ultimate determinant of GMP compliance in any organisation is culture — the shared values, behaviours, and expectations that define how people act when no one is watching. This module reinforces the 10 Golden Rules and the mindset that makes sustained GMP compliance possible.
The 10 Golden Rules — In Context
The 10 Golden Rules of GMP distil the requirements of PIC/S GMP Part 1, ICH guidelines, and international regulatory expectations into a practical, memorable framework. They apply to every person in every GMP role — regardless of seniority, department, or job title.
What is GMP Compliance Culture?
A GMP compliance culture is one where everyone — from the CEO to the newest production operator — understands why GMP matters, feels personally responsible for compliance, and is empowered to raise concerns without fear of negative consequences. Culture cannot be written into a policy document — it must be demonstrated, modelled, and reinforced by leaders at every level.
A strong GMP culture values "right first time" — doing each step correctly and fully the first time it is performed, in accordance with approved procedures. This reduces reliance on inspection and testing to catch errors, and instead prevents them. The cost of "right first time" is always less than the cost of rework, investigation, and remediation.
Behaviours That Undermine GMP Culture
- Working from memory rather than consulting approved SOPs
- Pre-signing or backdating records to save time
- Saying "we always do it this way" to justify deviations
- Failing to report problems because you're afraid of consequences
- "Inspector mode" compliance — only doing things right when being watched
- Treating training as a box to tick rather than a genuine development opportunity
In GMP manufacturing, every shortcut, every falsified record, and every compliance failure has a potential victim — the patient who takes that medicine. When GMP feels like bureaucracy, it helps to remember who it is for. A patient cannot inspect the tablet they are about to swallow. They must trust that the person who made it followed every rule, every time.
Final Assessment
Congratulations on completing all nine modules of GMP Part 1. This final assessment covers all course content. You must score 80% or higher (12 of 15 correct) to receive your Certificate of Completion.
Course Complete!
You have successfully completed GMP Part 1 — PIC/S Good Manufacturing Practice training. Your Certificate of Completion can be provided to your Quality Manager, HR Department, or included with job applications.
It may be provided to the Quality Manager, Supervisor, or HR Department.
eLearning does not replace onsite, product-specific, or site-specific GMP training.